Research identifies anillin as a potential prognostic biomarker for poorer outcomes in adrenocortical carcinoma, suggesting its therapeutic relevance.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
YAMASHITA et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: